Dalovisio J R, Pankey G A
J Infect Dis. 1978 Mar;137(3):318-21. doi: 10.1093/infdis/137.3.318.
Infections due to Runyon group IV atypical mycobacteria, Mycobacterium fortuitum and Mycobacterium chelonei, in humans have been difficult to treat in the past because of the organisms' resistance to all of the conventional antimycobacterial drugs. Determinations of minimal inhibitory concentrations (MICs) by the agar dilution method suggest that amikacin may be useful in the treatment of infections due to M. fortuitum and M. chelonei. Further support for the efficacy of antimicrobial agents with good in vitro activity in the treatment of infections with M. fortuitum and M. chelonei will depend on correlation of future clinical experience with standardized data on the MICs for these organisms.
过去，鲁尼恩IV群非结核分枝杆菌（偶然分枝杆菌和龟分枝杆菌）引起的人类感染很难治疗，因为这些微生物对所有传统抗分枝杆菌药物均具有耐药性。采用琼脂稀释法测定的最低抑菌浓度（MIC）表明，阿米卡星可能对治疗偶然分枝杆菌和龟分枝杆菌引起的感染有用。对于在治疗偶然分枝杆菌和龟分枝杆菌感染方面具有良好体外活性的抗菌药物疗效的进一步支持，将取决于未来临床经验与这些微生物MIC标准化数据之间的相关性。
